Inovio Pharmaceuticals (NASDAQ:INO) Stock Breaks Above Two Hundred Day Moving Average – Should You Sell?

Inovio Pharmaceuticals, Inc. (NASDAQ:INO)’s share price crossed above its 200-day moving average during trading on Monday. The stock has a 200-day moving average of $1.27 and traded as high as $2.17. Inovio Pharmaceuticals shares last traded at $1.89, with a volume of 221,083,904 shares traded.

Key Inovio Pharmaceuticals News

Here are the key news stories impacting Inovio Pharmaceuticals this week:

• Positive Sentiment: The FDA granted accelerated approval to VOCERYQ (INO-3107) for recurrent respiratory papillomatosis (RRP). The treatment is described as the first FDA-approved DNA medicine, potentially validating Inovio’s platform and opening a path to further pipeline opportunities. Article: Inovio: Upgrading To ‘Buy’ On Voceryq Accelerated Approval RRP And Competitive Advantages
• Positive Sentiment: HC Wainwright upgraded INO to Buy from Neutral and set a $5 price target. The firm also raised its 2027 EPS outlook, now forecasting a smaller full-year loss of $0.03 per share versus its previous $0.21 estimate, with positive earnings projected for the second half. Article: HC Wainwright Upgrades Inovio Pharmaceuticals to Buy
• Neutral Sentiment: VOCERYQ’s commercial prospects remain to be demonstrated. The Seeking Alpha analysis cites competition from Precigen’s PAPZIMEOS, while pointing to possible advantages for VOCERYQ in safety, dosing convenience and injection burden. Article: Inovio: Upgrading To ‘Buy’ On Voceryq Accelerated Approval RRP And Competitive Advantages
• Negative Sentiment: After a dramatic post-approval rally, shares have retreated, potentially as investors take profits and weigh the risks of launching a new treatment against competition and execution uncertainty. The approval and analyst upgrade remain supportive, but they do not guarantee commercial uptake. Article: Inovio’s VOCERYQ Data Cut Both Ways as Launch Clock Starts Ticking

Wall Street Analysts Forecast Growth

INO has been the subject of a number of analyst reports. Piper Sandler restated an “overweight” rating and issued a $4.00 price objective on shares of Inovio Pharmaceuticals in a research note on Monday, August 3rd. HC Wainwright set a $5.00 target price on shares of Inovio Pharmaceuticals and gave the stock a “buy” rating in a report on Monday. Jefferies Financial Group raised shares of Inovio Pharmaceuticals from a “hold” rating to a “positive” rating and boosted their target price for the stock from $1.80 to $3.00 in a research report on Thursday, August 13th. Zacks Research downgraded Inovio Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Monday, October 12th. Finally, Wall Street Zen raised Inovio Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Saturday, August 15th. Five analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $4.00.

Inovio Pharmaceuticals Stock Down 2.4%

The business’s fifty day simple moving average is $1.17 and its two-hundred day simple moving average is $1.27.

Inovio Pharmaceuticals (NASDAQ:INO) last announced its quarterly earnings data on Wednesday, August 12th. The biopharmaceutical company reported ($0.07) EPS for the quarter, beating analysts’ consensus estimates of ($0.22) by $0.15. On average, equities research analysts predict that Inovio Pharmaceuticals, Inc. will post -0.74 earnings per share for the current year.

Institutional Trading of Inovio Pharmaceuticals

Hedge funds have recently modified their holdings of the company. Squarepoint Ops LLC raised its stake in shares of Inovio Pharmaceuticals by 46.5% in the second quarter. Squarepoint Ops LLC now owns 36,391 shares of the biopharmaceutical company’s stock valued at $40,000 after purchasing an additional 11,554 shares in the last quarter. Headlands Technologies LLC bought a new stake in Inovio Pharmaceuticals in the second quarter valued at about $33,000. Engineers Gate Manager LP acquired a new position in Inovio Pharmaceuticals in the second quarter worth about $37,000. Green Alpha Advisors LLC raised its position in Inovio Pharmaceuticals by 68.8% in the third quarter. Green Alpha Advisors LLC now owns 114,857 shares of the biopharmaceutical company’s stock worth $140,000 after purchasing an additional 46,802 shares in the last quarter. Finally, Prime Capital Investment Advisors LLC lifted its stake in Inovio Pharmaceuticals by 312.4% during the third quarter. Prime Capital Investment Advisors LLC now owns 70,636 shares of the biopharmaceutical company’s stock worth $86,000 after purchasing an additional 53,510 shares during the period. Institutional investors own 26.79% of the company’s stock.

Inovio Pharmaceuticals Company Profile

Inovio Pharmaceuticals, Inc is a biotechnology company focused on developing DNA medicines, including DNA-based vaccines and immunotherapies designed to treat or prevent infectious diseases, cancers and other serious conditions. The company’s platform is intended to stimulate targeted immune responses by delivering DNA medicines into cells.

Inovio’s product pipeline has included investigational therapies such as INO-3107, a DNA immunotherapy being developed for recurrent respiratory papillomatosis, and other candidates targeting cancer and infectious diseases.